GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aditxt Inc (NAS:ADTX) » Definitions » Inventory-to-Revenue

Aditxt (Aditxt) Inventory-to-Revenue : 8.56 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Aditxt Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Aditxt's Average Total Inventories for the quarter that ended in Mar. 2024 was $0.68 Mil. Aditxt's Revenue for the three months ended in Mar. 2024 was $0.08 Mil. Aditxt's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 8.56.

Aditxt's Inventory-to-Revenue for the quarter that ended in Mar. 2024 declined from Dec. 2023 (9.90) to Dec. 2023 (8.56)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Aditxt's Days Inventory for the three months ended in Mar. 2024 was 946.37.

Inventory Turnover measures how fast the company turns over its inventory within a year. Aditxt's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.10.


Aditxt Inventory-to-Revenue Historical Data

The historical data trend for Aditxt's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aditxt Inventory-to-Revenue Chart

Aditxt Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventory-to-Revenue
Get a 7-Day Free Trial - - 4.71 0.77 1.32

Aditxt Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.93 4.03 7.57 9.90 8.56

Competitive Comparison of Aditxt's Inventory-to-Revenue

For the Biotechnology subindustry, Aditxt's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aditxt's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aditxt's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aditxt's Inventory-to-Revenue falls into.



Aditxt Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Aditxt's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Inventory-to-Revenue (A: Dec. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )
=( (0.95 + 0.746) / 2 ) / 0.645
=0.848 / 0.645
=1.31

Aditxt's Inventory-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue (Q: Mar. 2024 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Dec. 2023 ) + Total Inventories (Q: Mar. 2024 )) / count ) / Revenue (Q: Mar. 2024 )
=( (0.746 + 0.623) / 2 ) / 0.08
=0.6845 / 0.08
=8.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aditxt  (NAS:ADTX) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Aditxt's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2024 )/Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=0.6845/0.066*365 / 4
=946.37

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Aditxt's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2024 ) / Average Total Inventories (Q: Mar. 2024 )
=0.066 / 0.6845
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aditxt Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aditxt's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Aditxt (Aditxt) Business Description

Traded in Other Exchanges
N/A
Address
737 North Fifth Street, Suite 200, Richmond, VA, USA, 23219
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes a tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues.
Executives
Charles Athle Nelson director 11-F, BUILDING 12, SUNKING PLAZA, GAOJIAO ROAD, HANGZHOU, ZHEJIANG F4 311122
Bnp Paribas Securities Corp 10 percent owner 787 SEVENTH AVE, NEW YORK NY 10019
Matthew Shatzkes officer: Chief Legal Officer and GC 737 N. FIFTH STREET, SUITE 200, RICHMOND VA 23219
Lauren Chung director 1620 BEACON STREET, OXNARD CA 93033
Thomas J Farley officer: PRINCIPAL ACCOUNTING OFFICER 2569 WYANDOTTE ST., SUITE 101, MOUNTAIN VIEW CA 94043
Jeffrey W. Runge director C/O PHARMATHENE, INC., ONE PARK PLACE, SUITE 450, ANNAPOLIS MD 21401
Rowena Albanna officer: CHIEF OPERATING OFFICER 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Rosland Fisher Mcleod director 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Pankovcin Corinne officer: CHIEF FINANCIAL OFFICER BUSINESS DEVELOPMENT CORP OF AMERICA, 405 PARK AVENUE, 14TH FLOOR, NEW YORK NY 10022
Laura E Anthony director LAURA ANTHONY, 120 S. OLIVE AVE, WEST PALM BEACH FL 33401
Namvar Kiaie director 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Brian Michael Brady director 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Amro A. Albanna director, officer: CHIEF EXECUTIVE OFFICER 871 MARLBOROUGH AVENUE, SUITE 100, RIVERSIDE CA 92507
Shahrokh Shabahang director, officer: CHIEF INNOVATION OFFICER 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354

Aditxt (Aditxt) Headlines

From GuruFocus